| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/22/2004 | US20040142968 Premenstrual tension; irritable bowel disorders; administering local anesthetic; injected as nontoxic gel or oral capsule |
| 07/22/2004 | US20040142959 Method of treatment |
| 07/22/2004 | US20040142944 Compositions for nasal application |
| 07/22/2004 | US20040142914 Extended transdermal contraceptive regimens |
| 07/22/2004 | US20040142904 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 07/22/2004 | US20040142903 micronized fenofibrate in combination with cyclodextrin, a metal docusate or lauryl sulfate and a water insoluble dispersable carrier |
| 07/22/2004 | US20040142902 cholesterol lowering agent provided parenterally in a sustained release dosage form, e.g., as an injected matrix or stored within a drug delivery device; fewer side effects; reduces compliance problems with oral dosage |
| 07/22/2004 | US20040142867 Stabilized proteinic preparation |
| 07/22/2004 | US20040142475 Delivery systems for bioactive agents |
| 07/22/2004 | US20040142474 Liposomic structure comprising polyethylenimine (PEI), a fatty acid, cholesterol and polyethylene glycol for use as gene transfer tool in tissue engineering |
| 07/22/2004 | US20040142421 Pacemake ion channel proteins and uses thereof |
| 07/22/2004 | US20040142391 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with RAGE |
| 07/22/2004 | US20040142043 spray-dried fine powder comprising an active protein and a saccharide such as mannitol or cyclodextrin having a particle diameter of 10 mu m or less uniformly dispersed in the matrix of a biodegradable polymer |
| 07/22/2004 | US20040142042 providing prolonged release of thyrotropin-releasing hormone in situ at the central nervous system locus over a period of time by in situ stereotaxic implantation |
| 07/22/2004 | US20040142041 alumina particles, silica particles or alumina coated particles as carrier having a functional compound adsorbed on the surface that is released when exposed to an environmental or chemical condition |
| 07/22/2004 | US20040142040 Formulation and dosage form providing increased bioavailability of hydrophobic drugs |
| 07/22/2004 | US20040142038 Three layer artificial tear formulation |
| 07/22/2004 | US20040142036 unit aliquot dose of a pharmaceutical electricstatically deposited on a porous, permeable or semi-permeable ingestible membrane; including two or more active pharmaceuticals segregated from one another in a single delivery package. |
| 07/22/2004 | US20040142035 Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
| 07/22/2004 | US20040142034 Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators |
| 07/22/2004 | US20040142033 releases the following quantities of oxcarbazepine:15 min: 55 to 85%30 min: 75 to 95%45 min: 85 to 100%60 min: 90 to 100%in vitro |
| 07/22/2004 | US20040142031 carrier containing more than 10% by weight of a water-insoluble starch; shelf-life under relatively dry circumstances is enhanced. |
| 07/22/2004 | US20040142030 Stabilized tibolone compositions |
| 07/22/2004 | US20040142029 cellulose polymer, a methacrylic polymer and an active ingredient homogeniously distributed in a molecular state in an atomized matrix; also contains an organic base or an alkaline salt; and an adsorbent |
| 07/22/2004 | US20040142028 carrier containing more than 10% by weight of a water-insoluble starch; shelf-life under relatively dry circumstances is enhanced. |
| 07/22/2004 | US20040142026 pulmonary administration of a liposomal/complexed antiinfective to treat or ameliorate a pulmonary infection in a cystic fibrosis patient; administrated amount is 50% or less of the comparative free drug amount |
| 07/22/2004 | US20040142025 providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber; prepared rapidly at low pressure |
| 07/22/2004 | US20040142024 Patch formulation for external use |
| 07/22/2004 | US20040142023 rosin ester which provides a crystal inhibiting and drug stabilizing effect; capable of achieving zero-order kinetics for delivery of the active agent for a prolonged period of time |
| 07/22/2004 | US20040142022 exposure to electron beam radiation, preferably low level electron beam radiation, to produce sterilized patch for transdermal delivery |
| 07/22/2004 | US20040142021 System and methods for local intradermal treatment |
| 07/22/2004 | US20040142013 solid component such as a surgical screw with indentations formed in its surface and spherical particles bound to the indentation that are designed to provide controlled release of antimicrobial compound to treat osteomyelitis. |
| 07/22/2004 | US20040142012 Geometry retainable devices for body cavities |
| 07/22/2004 | US20040142000 Immune activator |
| 07/22/2004 | US20040141949 Treatment of mucositis |
| 07/22/2004 | US20040141926 Cosmetic composition for the hair with a waxy effect, in aerosol form |
| 07/22/2004 | US20040141925 Nanoparticles; therapy of arthritis, skin disorders, blood disorders, kidney disorders, eye disorders, thyroid, intestinal disorders, cancer, allergic reactions, asthma, contact dermatitis, atopic dermatitis, seasonal allergic rhinitis |
| 07/22/2004 | US20040141923 propellant free; for transmucosal administration |
| 07/22/2004 | US20040141921 Contrast agents |
| 07/22/2004 | US20040140374 Prefilming atomizer |
| 07/22/2004 | US20040139908 Formation of small crystals |
| 07/22/2004 | US20040139888 Containing nanofillers providing superior performance; refractive index, transparency reflection, resistivity, permittivity, permeability, coercivity, magnetic hysteresis, breakdown voltage; increased surface area, constrained domain sizes |
| 07/22/2004 | US20040139705 Packaging materials for transdermal drug delivery systems |
| 07/22/2004 | US20040139624 Methods and apparatus for making particles using spray dryer and in-line jet mill |
| 07/22/2004 | DE202004003404U1 Pharmazeutische Zusammensetzung zur kontrollierten Freisetzung von Wirkstoffen A pharmaceutical composition for controlled release of active ingredients |
| 07/22/2004 | DE10300984A1 Kapsel zur Aufnahme eines inhalativ applizierbaren Wirkstoffs Capsule for receiving a drug administered by inhalation |
| 07/22/2004 | DE10300325A1 Granulat mit öliger Substanz, Herstellungsverfahren und Tablette Granules with an oily substance, manufacturing processes and tablet |
| 07/22/2004 | CA2764405A1 Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| 07/22/2004 | CA2708895A1 Compositions, methods and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
| 07/22/2004 | CA2552690A1 Transdermal delivery using encapsulated agent activated by ultrasound and/or heat |
| 07/22/2004 | CA2522750A1 Immobilisation of dna-labelled lipid vesicles on dna arrays |
| 07/22/2004 | CA2513273A1 Method of encapsulating an active lipid-soluble substance by preparing a pit emulsion and emulsion obtained |
| 07/22/2004 | CA2512735A1 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 07/22/2004 | CA2512170A1 Pelletizing yew biomass for extraction of taxanes and other natural products |
| 07/22/2004 | CA2511963A1 Methods for making pharmaceutical dosage forms containing active cushioning components |
| 07/22/2004 | CA2511555A1 Aerosolizable pharmaceutical formulation for fungal infection therapy |
| 07/22/2004 | CA2511546A1 Active agent delivery device having composite members |
| 07/22/2004 | CA2511540A1 Acid labile drug compositions |
| 07/22/2004 | CA2511523A1 Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
| 07/22/2004 | CA2511512A1 Immunogenic compositions containing phospholipid |
| 07/22/2004 | CA2511385A1 Non-hygroscopic formulation comprising a hydroscopic drug |
| 07/22/2004 | CA2511376A1 Methods and apparatus for making particles using spray dryer and in-line jet mill |
| 07/22/2004 | CA2511313A1 Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| 07/22/2004 | CA2510903A1 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 07/22/2004 | CA2509755A1 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 07/22/2004 | CA2509261A1 Solid dispersions comprising a hygroscopic and/or deliquescent drug |
| 07/22/2004 | CA2508726A1 Methods for rapid identification of pathogens in humans and animals |
| 07/22/2004 | CA2508279A1 Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| 07/22/2004 | CA2507971A1 Compositions, methods, and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
| 07/22/2004 | CA2488104A1 Coated micromesh dental devices overcoated with imbedded particulate |
| 07/21/2004 | EP1439226A2 A nucleic acid antisense sequence to a polynucleotide encoding a polypeptide having heparanese activity |
| 07/21/2004 | EP1439193A2 Antibody directed to polypeptide having heparanase activity |
| 07/21/2004 | EP1439190A1 Growth differentiation factor-5 |
| 07/21/2004 | EP1438983A1 Elektro-release systems, modified electrodes and their use |
| 07/21/2004 | EP1438974A2 pH-sensitive liposomes based on diacyl-glycero-phosphoethanolamine and diacyl-succinyl-glycerol |
| 07/21/2004 | EP1438967A2 Pharmaceutical compositions of fibrinolytic agent |
| 07/21/2004 | EP1438965A1 Use of extracts from Hoodia gordonii and Hoodia lugardii for the preparation of a medicament for use in the suppression of appetite |
| 07/21/2004 | EP1438961A1 Bioequivalent composition of itraconazole dispersed in a hydrophilic polymer |
| 07/21/2004 | EP1438960A1 Compostion of itraconazole dispersed in a hydrophilic polymer having enhanced bioavailability |
| 07/21/2004 | EP1438959A1 Controlled release oxycodone compositions |
| 07/21/2004 | EP1438957A1 Benzothiophene formulations of a specific dosage |
| 07/21/2004 | EP1438955A1 High dose liposomal aerosol formulations |
| 07/21/2004 | EP1438942A1 An otorhinological drug delivery device |
| 07/21/2004 | EP1438405A1 Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene |
| 07/21/2004 | EP1438098A1 Microdevice and method of delivering or withdrawing a substance through the skin of an animal |
| 07/21/2004 | EP1438092A2 Transdermal transport device with an electrolytic actuator |
| 07/21/2004 | EP1438087A2 System for administering a drug delivery device |
| 07/21/2004 | EP1438076A1 Radiopharmaceutical agent for the treatment of early stage cancer |
| 07/21/2004 | EP1438074A2 Adjuvant compositions |
| 07/21/2004 | EP1438072A2 Polysaccharide-based network and method for the production thereof |
| 07/21/2004 | EP1438071A1 Therapies for treating respiratory diseases |
| 07/21/2004 | EP1438069A1 Enzyme inhibitors for inactivating allergens |
| 07/21/2004 | EP1438060A2 Prevention and treatment of restenosis by local administration of drug |
| 07/21/2004 | EP1438059A1 Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 07/21/2004 | EP1438055A1 D-tagatose as an anti-biofilm agent |
| 07/21/2004 | EP1438040A1 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
| 07/21/2004 | EP1438033A2 Hard capsules based on polysaccharide and method for the production thereof |
| 07/21/2004 | EP1438032A2 Production of starch-gel-based shaped bodies |
| 07/21/2004 | EP1438031A1 Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
| 07/21/2004 | EP1438030A2 Modified release dosage forms |